Evaluation of opsonophagocytic dysfunctions in severely burned patients by luminol-dependent chemiluminescence.
We compared the luminol-dependent chemiluminescence (CL) response of peripheral blood from severely burned patients with that from normal controls to evaluate the primary defense level against bacterial infection in the patients. The CL was measured upon addition to diluted whole blood of a soluble stimulus, phorbol myristate acetate (PMA) or particulate stimuli such as bacteria or zymosan without special opsonization. In the early post-burn days, the initial rate of whole blood CL induced with the particulate stimulus was much lower than that in the normal controls, whereas the rate was higher when PMA was used as a stimulus. The number of granulocytes in the patients' blood had increased and isolated polymorphonuclear leukocytes (PMNs) from the patients exhibited higher CL responses to the particulate or soluble stimulus as compared with those of normal controls. The results suggest that the PMNs in burn patients were activated and normally mobilized in the early post-burn period but the opsonizing capacity in the blood decreased. In fact, the serum levels of complement, immunoglobulins and fibronectin were found to be lower in the blood from the patients than those from normal controls and a supplement of freshly frozen plasma of human immunoglobulin preparations restored the initial rate of the whole blood CL upon phagocytosis. The prognosis is still poor when severe infection occurs in the patients with decreased CL response of whole blood. Recombinant human granulocyte colony-stimulating factor (rh G-CSF) enhanced the CL response of PMNs from burn patients. The administration of rhG-CSF may be useful for decreasing the morbidity of severe infection following burn injury in the near future.
Ono
Y
Y
Second Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Kunii
O
O
Kobayashi
K
K
Kanegasaki
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002056:Burns / Q000150:complications / Q000276:immunology*; D002648:Child; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000097:blood; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007275:Injections, Intravenous; D007958:Leukocyte Count; D008163:Luminescent Measurements; D008165:Luminol / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology*; D009895:Opsonin Proteins / Q000097:blood*; D010587:Phagocytosis / Q000276:immunology*; D010949:Plasma / Q000276:immunology; D011379:Prognosis; D011552:Pseudomonas Infections / Q000209:etiology; D013203:Staphylococcal Infections / Q000209:etiology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors; D015054:Zymosan / Q000494:pharmacology
D007136:Immunoglobulins; D009895:Opsonin Proteins; D016179:Granulocyte Colony-Stimulating Factor; D008165:Luminol; D015054:Zymosan; D013755:Tetradecanoylphorbol Acetate